Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus—is metabolic reprogramming the mechanism for these favorable outcomes?
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.